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Abstract
Background: To potentially improve outcomes in pancreatic resection, robot-assisted pancreatic
surgery has been introduced. This technique has possible advantages over laparoscopic surgery, such as
its affordance of three-dimensional vision and increased freedom of movement of instruments. A sys-
tematic review was performed to assess the safety and feasibility of robot-assisted pancreatic surgery.
Methods: The literature published up to 30 September 2011 was systematically reviewed, with no
restrictions on publication date. Studies reporting on over five patients were included. Animal studies,
studies not reporting morbidity and mortality, review articles and conference abstracts were excluded.
Data were extracted and weighted means were calculated.
Results: A total of 499 studies were screened, after which eight cohort studies reporting on a total of 251
patients undergoing robot-assisted pancreatic surgery were retained for analysis. Weighted mean opera-
tion time was 404  102 min (510  107 min for pancreatoduodenectomy only). The rate of conversion
was 11.0% (16.4% for pancreatoduodenectomy only). Overall morbidity was 30.7% (n = 77), most
frequently involving pancreatic fistulae (n = 46). Mortality was 1.6%. Negative surgical margins were
obtained in 92.9% of patients. The rate of spleen preservation in distal pancreatectomy was 87.1%.
Conclusions: Robot-assisted pancreatic surgery seems to be safe and feasible in selected patients and,
in left-sided resections, may increase the rate of spleen preservation. Randomized studies should
compare the respective outcomes of robot-assisted, laparoscopic and open pancreatic surgery.
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Introduction
Pancreatic resection is amongst the most complex and challeng-
ing of abdominal operations. Even in highly experienced centres,
open pancreatic surgery is associated with morbidity rates of
30–40% and mortality rates of approximately 2%.1,2 New,
minimally invasive techniques may reduce postoperative mor-
bidity. Therefore, in recent years, laparoscopic pancreatic surgery
has been introduced as an alternative to open surgery.3 Laparo-
scopic techniques have potential benefits; they can decrease pain
and blood loss, and result in fewer complications, faster recovery
and a shorter hospital length of stay (LoS).4,5 Early experiences
have shown that laparoscopic pancreatic surgery is safe and fea-
sible in selected patients, and that morbidity rates range from
16% to 40%.6–10 Although a growing number of studies on
laparoscopic pancreatic surgery have been published, it has not
gained wide acceptance. This is probably explained by the
known limitations of conventional laparoscopic surgery, such as
the decreased range of motion this technique affords and the
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two-dimensional vision of the operative field, which make its
practice difficult.
The use of a robotic system may overcome some of these short-
comings. Robot-assisted surgery provides three-dimensional
vision and a magnified view of the operative field. These advan-
tages, combined with the increased freedom of movement of sur-
gical instruments and the elimination of tremor, lead to improved
precision in operative technique and may lead to safer anastomo-
ses compared with laparoscopic pancreatic surgery. Moreover,
robotic systems are ergonomically better for the surgeon and
cause less weariness during the operation. In other gastrointestinal
procedures, such as oesophageal resection, several centres have
gained extensive experience in robot-assisted surgery, including
the University Medical Centre Utrecht (UMCU), with the first
robot-assisted oesophagectomy reported in 2003.11,12 The first
patient to undergo robot-assisted pancreatic surgery was also
reported in that year.13 Since then, a small number of centres have
adopted this technique and several small series have reported
encouraging outcomes.
In preparation for a possible expansion of the UMCU pro-
gramme in robot-assisted surgery from oesophagogastric to
pancreatic surgery, a systematic review of the current literature
was performed. The aim was to assess the safety and feasibility of
robot-assisted laparoscopic pancreatic surgery according to early
experiences of the use of this technique.
Materials and methods
Literature search strategy
A systematic search, restricted to papers published in English,
was performed in MEDLINE (for articles published from
1947 to 30 September 2011) and EMBASE (for articles pub-
lished from 1974 to 30 September 2011). The review pro-
tocol was developed according to the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses)
guidelines.14
Search terms were ‘[robot OR robotic OR (da Vinci)] AND
(pancreas OR pancreatic OR pancreatectomy OR pancreati-
coduodenectomy OR Whipple)’. Titles and abstracts of the iden-
tified papers were screened by two authors (MS and HCvS). Any
differences in opinion were resolved by discussion and, if neces-
sary, the input of a third author (MGB). Full-text versions of
papers considered for inclusion were examined. The bibliogra-
phies of selected articles were reviewed for other potentially rel-
evant studies.
In order to diminish selection bias, studies were required to
report a cohort of at least five patients undergoing robot-assisted
pancreatic surgery to be considered for inclusion. Animal studies,
studies not reporting morbidity and mortality, review articles and
conference abstracts published in abstract form only were
excluded. If multiple studies were published by one centre, the
study reporting the largest number of patients was selected unless
it was clear that data did not overlap.
Data extraction
Study characteristics extracted from the selected articles included
country, study design, study interval, number of patients under-
going robot-assisted pancreatic surgery, total number of patients
in the study, type of operation and whether comparisons among
open, laparoscopic and robot-assisted surgery were made.
Documented patient characteristics included sex, age, body
mass index (BMI), preoperative health status scoring and
pathology.
Data on outcomes of surgery were extracted, if available, and
included operating time, estimated blood loss, conversion rate,
complications and mortality as defined by the individual papers,
hospital LoS, pathology findings as defined by the individual
papers and, in cases of distal pancreatectomy, the rate of spleen
preservation.
If a study reported the outcomes of open and/or laparoscopic
procedures, these data were also collected.
Authors of studies that did not report outcomes separately for
distal pancreatectomies and pancreaticoduodenectomies were
contacted to obtain additional data.
Statistical analysis
If outcomes were represented as medians and ranges, means
and standard deviations (SDs) were estimated according to the
methods described by Hozo et al.15 A weighted mean and
weighted SD were calculated. In the present review, the outcomes
presented in tables are given as they were originally reported in the
individual articles. If studies reported outcomes separately for
pancreatoduodenectomy or distal pancreatectomy, these data
were also included in an analysis of this particular type of
procedure.
Results
The literature search identified a total of 499 potentially relevant
articles, of which eight studies were ultimately included in this
systematic review (Fig. 1).
Characteristics of the included studies are presented in Table 1.
All studies were retrospective, non-controlled case series (Oxford
level 4 evidence)16 and hence methodological quality was not
determined. Some studies reported that data had been collected
prospectively.17–19 Four studies compared outcomes in patients
who underwent robot-assisted surgery with outcomes in
patients who underwent laparoscopic and/or open pancreatic
resections.17,20–22 Two studies reported outcomes in a single cohort
undergoing different types of procedure.18,23 The authors of these
studies were contacted to provide the specific outcomes of surgery
for each operation type. Together, the eight studies referred to a
total of 251 patients undergoing robot-assisted pancreatic surgery.
The median number of relevant patients included in each study
was 15 (range: five to 134 patients). Resections included 131 pan-
creatoduodenectomies (52.2%) and 85 distal pancreatectomies
(33.9%).
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With regard to definitions of complications and mortality, four
studies provided no definitions at all.17,18,20,24 In the remaining
studies definitions varied widely. For example, the four papers
reporting pancreatic fistula all used different definitions.19,21–23
Two of the studies used the internationally accepted International
Study Group on Pancreatic Fistula (ISGPF) definition,19,21 one of
these reported grade B and C fistulae only.21 Another study used
the John Hopkins definition to identify fistulae, but graded some
of the fistulae according to the ISGPF classification.23 The fourth
study used a definition based on that of Bertrand.22 Delayed
gastric emptying (DGE) was defined in only one study,19 which
used the International Study Group on Pancreatic Surgery
(ISGPS) classification.25 Bleeding was defined in none of the
studies. Complication rates were also reported differently. One
study presented 30-day morbidity,19 but others did not report the
time period in which complications occurred. Only one study
used a validated classification system (i.e. the Clavien–Dindo sys-
tem26) to grade complications.19 None of the studies provided a
definition of pathological margins.
Patient characteristics
Characteristics of the included patients are summarized in
Table 2. The weighted mean age of all patients included was
60  12 years. Two studies reported patient BMI,19,20 providing a
weighted mean of 26.2 4.5 kg/m2. Indications for surgery varied
from pseudocyst to carcinoma. Of all resections, 115 procedures
were performed because of malignancy (45.8%). In 123 pancrea-
toduodenectomies (93.9% of all pancreatoduodenectomies) and
83 distal pancreatectomies (97.6% of all distal pancreatectomies),
indications were reported separately for this type of procedure.
Malignant disease was cited as the indication for surgery in 72.4%
(n = 89) of pancreatoduodenectomies and 20.5% (n = 17) of distal
pancreatectomies. One of the studies also reported a palliative
procedure.18
With respect to scoring of the patients’ preoperative health
status, two studies provided data on preoperative American
Society of Anesthesiologists (ASA) class.17,19 Zeh et al. reported
ASA classes of 2 in 21 patients (42.0%), 3 in 28 patients (56.0%)
and 4 in one patient (2.0%).19 Waters et al. reported only a mean
ASA score of 2.8.17
Outcomes
Outcomes in the eight studies are represented in Table 3. Weighted
mean operation time was 404  102 min. Estimated blood loss
was described in all but one series.24 Weighted mean blood loss
amounted to 328  334 ml.
A total of 27 of the 254 (10.6%) robot-assisted procedures had
to be converted to open surgery and one (0.4%) was converted
to conventional laparoscopic surgery.17 Reasons for conversion
were: bleeding (n = 1),24 arterial/venous abutment/infiltrations
(n = 9),19,23 local advancement in non-vascular structures
(n = 2),18,23 difficult dissection (n = 14),17,19,23,24 hypercapnia
(n = 1)23 and malfunction of the robot (n = 1).23
Complications occurred in 77 of 251 patients (30.7%). One
study reported the total complication rate, but did not report
types of complication.20 In the 231 patients included in the
remaining seven studies, 46 incidences of pancreatic fistula were
identified (19.9%). Three studies used the ISGPF classification
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Figure 1 Study selection
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scheme in at least a proportion of patients (n = 112). When grade
B and C fistulae only were considered, the fistula rate amounted to
11.6% (13 of 112 patients). Delayed gastric emptying occurred in
13 of 231 patients (5.6%). The study using the ISGPS classification
(which included 10 patients with DGE) reported that six patients
experienced grade B DGE and four experienced grade C events.19
Other complications included pulmonary complications (n =
13, 5.6%), bleeding (n = 10, 4.3%), intra-abdominal fluid collec-
tion (n = 9, 3.9%), cardiac complications (n = 7, 3.0%), throm-
boembolic events (n = 5, 2.2%), wound infection (n = 5, 2.2%),
urinary tract infection (n = 4, 1.7%), gastrointestinal complica-
tions (n = 4, 1.7%), biliary leak (n = 1, 0.4%) and requirements for
reoperation (n = 8, 3.5%). Four of 251 patients (1.6%) died. The
cause of death was reported in three patients and included sepsis
following Boerhaave syndrome (n = 1),23 colonic ischaemia (n =
1)23 and multi-system organ failure (n = 1).19 The latter occurred
in a patient with an ISGPF grade C fistula, who experienced a
complicated postoperative course not directly related to the pan-
creatic fistula.19
Weighted mean hospital LoS was 14.2  10.7 days.
Five studies reported pathological margin status in a total of
127 patients (Table 3).17,19,22–24 The number of resected lymph
nodes was described in four series.17,19,23,24 One of the series
reported these pathological findings only in patients under-
going pancreatoduodenectomy.23 Two of the five studies
reported findings of positive margins in the robot-assisted surgery
group (nine of 127 patients, 7.1%).19,23 The weighted mean
number of lymph nodes harvested was 15.3  7.6. All reported
positive surgical margins were found in patients undergoing
pancreatoduodenectomy.
Only two studies included in the current systematic review
reported on costs. Kang et al. reported mean per patient costs of
Table 1 Characteristics of included studies
Authors Year Country Study design Study interval Relevant
patientsa,
n
Patients
in studyb,
n
Procedure Comparison
Chan et al.18 2011 China Retrospective
non-controlled
case series
May 2009 to December
2010
12 55 Pancreatoduodenectomy
(n = 8), distal
pancreatectomy (n = 2),
double bypass (n = 1),
cystojejunostomy (n = 1)
None
Giulianotti et al.23 2010 USA Retrospective
non-controlled
case series
October 2000 to January
2009
134 134 Pancreatoduodenectomy
(n = 60), distal
splenopancreatectomy
(n = 23), distal
pancreatectomy
(spleen-preserving)
(n = 23), central
pancreatectomy (n = 3),
total pancreatectomy
(n = 1), enucleation
(n = 3), other (n = 21)c
None
Kang et al.20 (DP) 2011 South
Korea
Retrospective
non-controlled
case series
March 2006 to July 2010 20 45 Distal pancreatectomy Robot-assisted (n = 20)
versus laparoscopic
(n = 25)
Kang et al.21 (CP) 2011 South
Korea
Retrospective
non-controlled
case series
Robot-assisted: December
2007 to December 2009
Open: January 1990 to
November 2007
5 15 Central pancreatectomy Robot-assisted (n = 5)
versus open (n = 10)
Narula et al.24 2010 USA Retrospective
non-controlled
case series
May 2006 to June 2007 5 5 Pancreatoduodenectomy None
Waters et al.17 2010 USA Retrospective
non-controlled
case series
August 2008 to August
2009
17 57 Distal pancreatectomy Robot-assisted (n = 17)
versus laparoscopic
(n = 18) versus open
(n = 22)
Zeh et al.19 2011 USA Retrospective
non-controlled
case series
October 2008 to December
2010
50 50 Pancreatoduodenectomy None
Zhou et al.22 2011 China Retrospective
non-controlled
case series
January–December 2009 8 16 Pancreatoduodenectomy Robot-assisted (n = 8)
versus open (n = 8)
aPatients undergoing robot-assisted pancreatic resection.
bAll patients in study, including patients undergoing open pancreatic surgery or robot-assisted resections of other organs.
cOther: cystoduodenostomy (n = 1), cystogastrostomy (n = 14), cystojejunostomy (n = 3), pancreaticogastrostomy (n = 2), pancreaticojejunostomy
(n = 1).
DP, distal pancreatectomy; CP, central pancreatectomy.
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US$8305  870 for robot-assisted distal pancreatectomy and
US$3862  1724 for conventional laparoscopic surgery in
South Korea.20 Waters et al., who primarily addressed the cost-
effectiveness of robot-assisted distal pancreatectomy, reported
the direct costs of the operation and the entire hospital stay in a
US centre and cited mean per patient costs of US$11 904 for
robot-assisted surgery, US$12 900 for laparoscopic surgery and
US$15 521 for open surgery. This suggests that direct costs were
comparable between the particular approaches.17
Median follow-up was reported in two studies,21,24 which cited
a maximum duration of 19 months (range: 16–24 months).21
Giulianotti et al. reported follow-up periods in particular sub-
groups; the longest period mentioned was 106 months.23
Pancreatoduodenectomy
Outcomes of pancreatoduodenectomies were analysed separately.
One study reported outcomes of pancreatoduodenectomies and
other types of resection together18 and another study did not
separate morbidity and mortality in pancreatoduodenectomy
from those in other procedures.23 The authors of these studies
were contacted and provided additional data.
In the 131 pancreatoduodenectomies, weighted mean opera-
tion time was 510  107 min and weighted mean blood loss was
440  254 ml (Table 4). Twenty-two of 134 intended robot-
assisted procedures were converted to open surgery (16.4%).
Complications occurred in 51 patients (38.9%) and three patients
died (2.3%). Fistulae occurred in 34 patients (26.0%). Weighted
Table 2 Characteristics of patients reported in the included studies
Authors Male, % Age, years BMI Preoperative
status
Pathology
Chan et al.18 58% 71.5 (45–83)d NR NR ACA of pancreas (n = 4), ACA of biliary tract (n = 2),
CIS of biliary tract (n = 1), IPMN (n = 1), SCN (n =
1), NET (n = 1), SPN (n = 1), pseudocyst (n = 1)
Giulianotti et al.23 38% 58 (25–86)c NR NR PD: ACA of pancreas (n = 27), ACA of biliary tract
(n = 17), MCN (n = 5), chronic pancreatitis (n = 5),
duodenal pathology (n = 3), IPMN (n = 1), SPN
(n = 1), choledochal cyst (n = 1)
DP: non-malignant (n = 29), ACA of pancreas (n = 6),
NET (n = 5), cystic NET (n = 2), MCN (n = 2),
metastases (n = 2)
Kang et al.20 (DP) R: 40%
L: 44%
R: 44.5  15.9
L: 56.5  13.9b
R: 24.2  2.9
L: 23.4  2.6b
NR R: MCN (n = 5), SCN (n = 4), SPN (n = 4), NET (n =
3), IPMN (n = 2), pancreatitis (n = 1), IPAS (n = 1)
L: IPMN (n = 10), SPN (n = 4), SCN (n = 3), NET
(n = 3), MCN (n = 2), pseudocyst (n = 1), IPAS
(n = 1), benign stricture (n = 1)
Kang et al.21 (CP) R: 0%
O: 40%
R: 50.0  12.3
O: 38.7  16.5b
NR NR R: SPN (n = 4), NET (n = 1)
O: SPN (n = 3), NET (n = 3), MCN (n = 3), congenital
cyst (n = 1)
Narula et al.24 NR 51.6a NR NR Chronic inflammation and fibrosis (n = 4), ACA
(n = 1)
Waters et al.17 R: 35%
L: 50%
O: 45%
R: 64
L: 59
O: 59a
NR ASA:
R: 2.8
L: 2.9
O: 2.9a
R: IPMN (n = 6), NET (n = 5), MCN (n = 3), SCN
(n = 1), other (n = 2)
L: NET (n = 5), MCN (n = 3), SCN (n = 2), ACA
(n = 2), IPMN (n = 2), other (n = 3)
O: ACA (n = 11), NET (n = 4), IPMN (n = 4), MCN
(n = 2), other (n = 1)
Zeh et al.19 48% 68  16b 27  5b ASA:
II: 42.0%
III: 56.0%
IV: 2.0%
ACA of pancreas (n = 14), ACA of biliary tract
(n = 11), NET (n = 10), IPMN (n = 10), SPN (n = 2),
MCN (n = 1), duodenal adenoma (n = 1),
oligocystic SCN (n = 1)
Zhou et al.22 R: 62.5%
O: 50.0%
R: 64.4  9.1
O: 59.4  9.4b
NR NR R: ACA of biliary tract (n = 6), ACA of pancreas
(n = 1), periampullar ACA (n = 1)
O: ACA of biliary tract (n = 4), pancreatic ACA (n =
2), papilloma of biliary tract (n = 1), duodenal
papilloma (n = 1)
aMean.
bMean  standard deviation.
cMean (range).
dMedian (range).
BMI, body mass index; R, robot-assisted; L, laparoscopic; O, open; NR, not reported; ASA, American Society of Anesthesiologists; CP, central
pancreatectomy; DP, distal pancreatectomy; PD, pancreatoduodenectomy; ACA, adenocarcinoma; CIS, carcinoma in situ; IPAS, intrapancreatic
accessory spleen; IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; NET, neuroendocrine tumour; SCN, serous
cystic neoplasm; SPN, solid pseudopapillary neoplasm.
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mean LoS was 15.9  16.7 days. Positive surgical margins were
found in 10 of 115 patients in whom pathological margin status
was reported (8.7%). The number of lymph nodes harvested was
reported for 110 patients to give a weighted mean of 16 8 lymph
nodes.
Distal pancreatectomy
Four studies reported on distal pancreatectomy,17,18,20,23 but only
two reported outcomes for this type of resection separately
(including in 37 of the 85 patients undergoing robot-assisted
distal pancreatectomy).17,20 Authors were contacted and provided
additional data.18,23 Weighted mean operating time was 281 
102 min and weighted mean blood loss was 251  317 ml. Three
studies (including 65 patients) provided conversion rates; four
resections were converted to open surgery and one to a conven-
tional laparoscopic resection (7.7%).17,18,23 Fifteen patients suf-
fered complications (17.6%). In the studies that provided data on
pancreatic fistulae, the rate of fistulae was 16.1% (10 of 62
patients).17,18,23 There was no mortality and weighted mean hos-
pital LoS was 6.0  2.0 days. Two studies (n = 19) provided data
on pathological findings; these reported no positive surgical
margins. The study reporting the number of lymph nodes har-
vested (n = 17) cited a mean of five lymph nodes. All studies
describing distal pancreatectomy reported on the percentage of
spleen preservation: the spleen was preserved in 74 of 85 distal
pancreatectomies (87.1%).
Discussion
The combined data provided by the eight observational cohort
studies that fulfilled the criteria for inclusion in this systematic
Table 3 Outcomes of surgery (all types of resection)
Authors Operating
time, min
Blood loss, ml Conversion
rate, n (%)
Patients with
 1 complication,
n (%)
Postoperative
mortality,
n (%)
Hospital stay,
days
Positive
surgical
margins
Lymph nodes
harvested
Spleen-
preservation
in DP
Chan et al.18 478 (270–692)f 200 (30–300)f 1 (8.3%) 5 (41.7%) 0 12 (6–21)f NR NR 2/2 (100%)
Giulianotti et al.23 Italy: 312 (55–660)
USA: 351 (73–630)e
Italy: 261 (100–600)
USA: 342 (5–2000)e
Italy: 10 (13.0%)
USA: 4 (7.0%)
35 (26.1%) Italy: 2 (2.6%)
USA: 1 (1.8%)
Italy: 21.8 (6–85)
USA: 9.3 (3–30)e
PD:
Italy: 0
USA: 5 (20.8%)
PD:
Italy: 21 (5–37)
USA: 14 (12–45)e
42/46 (91.3%)
Kang et al.20 (DP) R: 348.7  121.8
L: 258  118.6d
R: 372.0  341.5
L: 420.2  445.5d
NR R: 2 (10.0%)
L: 4 (16.0%)
R: 0
L: 0
R: 7.1  2.2
L: 7.3  3.0d
NR NR R: 19/20 (95.0%)
L: 16/25 (64.0%)
Kang et al.21 (CP) R: 432.0  65.7
O: 286.5  90d
R: 275.0  221.7
O: 858.3  490d
0 R: 1 (20.0%)
O: 5 (50.0%)
R: 0
O: 0
R: 14.6  7.7
O: 22.1  13.3d
NR NR N/A
Narula et al.24 420 (360–510)e NR 3/8 (37.5%) 0 0 9.6c 0 16c N/A
Waters et al.17 R: 298 (191–418)
L: 224 (100–346)
O: 234 (136–437)e
R: 279 (20–1200)
L: 667 (50–7000)
O: 681 (50–3300)e
R: 2 (11.8%)
L: 2 (11.1%)
R: 3 (17.6%)
L: 6 (33.3%)
O: 4 (18.2%)
R: 0
L: 0
O: 0
R: 3.8 (2–6)
L: 6.4 (3–34)
O: 7.7 (3–25)e
R: 0
L: 0
O: 2 (9.1%)
R: 5
L: 11
O: 14c
R: 11/17 (64.7%)
L: 5/18 (27.7%)
O: 3/22 (13.6%)
Zeh et al.19 568 (536–629)g 350 (150–625)g 8 (16.0%) 28 (56.0%) 1 (2.0%) 10 (8–13)g 4 (10.8%)a 17  7da N/A
Zhou et al.22 R: 718.8  186.7
O: 420.0  127.2d
R: 153.8  43.4
O: 210  53.2d
0 R: 2 (25.0%)
O: 6 (75.0%)
R: 0
O: 1 (12.5%)
R: 16.4  4.1
O: 24.3  7.1d
R: 0
O: 1 (16.7%)b
NR N/A
aIn 37 malignant tumours.
bIn six malignant tumours.
cMean.
dMean  standard deviation.
eMean (range).
fMedian (range).
gMedian (interquartile range).
R, robot-assisted; L, laparoscopic; O, open; DP, distal pancreatectomy; PD, pancreatoduodenectomy; NR, not reported; N/A, not applicable.
Table 4 Outcomes of robot-assisted pancreatoduodenectomy
Authors Relevant
patientsa,
n
Operation
time, min
Blood loss, ml Conversion
rate
Patients with 1
complications,
n (%)
Postoperative
mortality,
n (%)
Hospital
stay, days
Positive
surgical
margins
Lymph
node
harvested
Chan et al.18 8 550.8  119.7e 156.3  101.6e 0 3 0 13.1  4.6e 4b 12  6e
Giulianotti et al.23 60 421 (240–660)f 394 (80–1500)f 11 (18.3%) 21 (35.0%) 2 (3.3%) 17.7 (5–85)f 5 (21%) Italy: 21 (5–37)
USA: 14 (12–45)f
Narula et al.24 5 420 (360–510)f NR 3/8 (37.5%) 0 0 9.6d 0 16d
Zeh et al.19 50 568 (536–629)g 350 (150–625)g 8 (16.0%) 28 (56.0%) 1 (2.0%) 10 (8–13)g 4 (10.8%)c 17  7eb
Zhou et al.22 8 718.8  186.7e 153.8  43.4e 0 2 (25.0%) 0 16.4  4.1e 0 NR
aRelevant patients: patients undergoing robot-assisted pancreatoduodenectomy.
bIn five malignant tumours.
cIn 37 malignant tumours.
dMean.
eMean  standard deviation.
fMean (range).
gMedian (interquartile range).
NR, not reported.
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review suggest that robot-assisted pancreatic surgery is feasible
and can be performed safely in selected patients.
As robot-assisted pancreatic surgery was introduced to poten-
tially improve current outcomes of surgery, the findings of this
systematic review were compared with outcomes reported for
open and laparoscopic pancreatic surgery. Table 5 summarizes
outcomes of recent studies of open and laparoscopic pancreatic
surgery. Compared with open or laparoscopic approaches, opera-
tion times are longer in robot-assisted surgery. Hospital stay may
be shorter in robot-assisted resections than in open or laparo-
scopic surgery. Conversion rates do not seem to be higher in
robot-assisted approaches than in conventional laparoscopic pan-
creatic surgery.
Reported morbidity rates in open and laparoscopic surgery
range from 16% to 45% and mortality rates range between 1%
and 2%.2,7,8,27,28 In the studies included in the current review, com-
plications occurred in 30.7% of patients and mortality in 1.6%.
This suggests that in selected patients, morbidity and mortality
rates in robot-assisted pancreatic surgery are comparable with
those in laparoscopic and open surgery. The most common com-
plication in the current study was pancreatic fistula, which
occurred at a rate of 19.9%. When only fistulae of ISGPF grades B
and C were considered, the rate of occurrence was 11.6%. Other
large open and laparoscopic series showed rates of pancreatic
fistulae of 12–36%.1,7,27 Only one study included in this review
reported on the texture of the pancreas.19 As a soft pancreatic
remnant is associated with a higher risk for fistula,29 this may have
been important in evaluating the risk for pancreatic fistula.
Four of the studies in this review directly compared the out-
comes of robot-assisted surgery with those of open and/or
laparoscopic pancreatic surgery in a non-randomized fashion
(Table 3).17,20–22 All studies showed longer operation times in
robot-assisted than in open or laparoscopic surgery. Less blood
loss21,22 and shorter hospital LoS17,22 were also observed. In distal
pancreatectomies, rates of spleen preservation were higher in
robot-assisted surgery than in open or laparoscopic approaches.
One study cited spleen preservation rates of 95% in robot-assisted
and 64% in laparoscopic surgery,20 and another cited rates of 65%
in robot-assisted, 28% in laparoscopic and 14% in open surgery.17
With reference to comparisons of the outcomes of robot-
assisted surgery with those of open or laparoscopic surgery, it
should be noted that the studies on robot-assisted surgery report
early experiences with this technique. This may imply that
healthier patients with easier tumours were selected for robot-
assisted surgery. Therefore, the resulting outcomes may be more
favourable than they would have been in an unselected patient
group. However, there is probably a considerable learning curve
involved in the evolution of experience in robot-assisted pancre-
atic resections.24 Learning curves have also been reported in other
types of robot-assisted surgery.12,30 Zeh et al. compared the out-
comes of a first set of 20 pancreatoduodenectomies with those of
a second set of 22 operations.31 In the latter group they observed
reductions of 295 ml in perioperative blood loss and 3 days in
hospital LoS compared with the first group. The rate of pancreatic
fistula decreased from 25% to 9%. Operation time, however, did
not decrease.31 Other data suggest that the set-up and docking
Table 5 Outcomes of open and laparoscopic pancreatic surgery in international centres of excellence
Authors Study
design
Patients, n Type of
procedure
Operation
time, min
Blood
loss, ml
Conversion
rate
Hospital
stay, days
Morbidity,
n (%)
Mortality,
n (%)
Spleen
preservation
in DP
Cameron
et al.
(2006)28
Retrospective
observational
cohort study
1970s: 2
1980s: 63
1990s: 587
2000s: 347
Open
PD
1970s: 528
1980s: 378
1990s: 366
2000s: 330f
1970s: 1090
1980s: 900
1990s: 700
2000s: 700f
N/A 1980s: 17
1990s: 11
2000s: 9f
41% 10 (1%) N/A
Winter
et al.
(2006)2
Retrospective
observational
cohort study
1175 Open
PD
380
(200–790)e
800
(150–15 000)e
N/A 9 (4–375)e 415 (38%) 26 (2%) N/A
Diener
et al.
(2011)27
Randomized
controlled trial
352 Open
DP
190.0  80.5c NR N/A 15.4  14.7c 157 (45%) 3 (1%) 59
(17%)
Gagner
et al.
(2009)8
Review 146 Laparoscopic
PD
439.3
(284–660)d
142.8
(50–770)d
46% 18 (7–39)d 23 (16%) 2 (1.3%) N/A
Borja-Cacho
et al.
(2009)7
Systematic
review
806 Laparoscopic
DP
199.1  83.5c 235.7  42.9c 74 (9.2%) 6.6  4.1c 284 (37.6%) 2 (0.2%) 400
(49.6%)
Present
study
Systematic
review
PD: 131
DP: 85
PD and DP PD: 510  107c
DP: 281  102c
PD: 440  254c
DP: 251  317c
PD: 22
(16.4%)a
DP: 5 (7.7%)b
PD: 15.9  16.7c
DP: 6.0  2.0c
PD: 51
(38.9%)
DP: 15
(17.6%)
PD: 3
(2.3%)
DP: 0
PD: N/A
DP: 74
(87.1%)
aOf 134 intended robot-assisted procedures.
bData for 65 patients.
cMean  standard deviation.
dMean (range).
eMedian (range).
fMedian.
PD, pancreatoduodenectomy; DP, distal pancreatectomy; N/A, not applicable; NR, not reported.
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time required in robot-assisted procedures can decrease as expe-
rience with the system increases. Iranmanesh et al. showed that
over the course of 96 procedures, set-up time decreased from
35 min to 15 min.32 When docking was carried out by inexperi-
enced surgeons (who had performed fewer than five dockings),
median docking time was 17.5 min (range: 10–70 min). Experi-
enced surgeons (who had performed more than 12 dockings)
demonstrated a median docking time of 8 min (range:
2–50 min).32
The promising outcomes of robot-assisted surgery shown in
this systematic review suggest that this approach offers the
advantages associated with minimally invasive surgery, such as
decreased pain and blood loss, fewer complications, faster recov-
ery and a shorter hospital LoS.4,5 Moreover, robot-assisted
procedures provide potential advantages over conventional
laparoscopic surgery: there is increased freedom of movement of
surgical instruments; tremor is eliminated, and 3D vision of the
operative field is available. This leads to more accurate movements
such as in resecting and suturing. Another important advantage
refers to the ergonomic benefits afforded to the surgeon by a
robot-assisted system.
There are several limitations to robot-assisted surgery. Firstly,
there is a lack of tactile feedback,19,33 although it has been sug-
gested that this is compensated for by improved visual feedback.23
Secondly, it may be difficult to operate in multiple quadrants of
the abdomen because of the risk for interference by the robotic
arms. The configuration of the ports can minimize arm interfer-
ence.19 Thirdly, robot-assisted surgery is probably associated with
longer operation time. Finally, robot-assisted surgery may incur
greater costs.
The shortcomings of the current systematic review include the
relatively small numbers of patients reported in the individual
studies included, which derive from single-institution series. Only
17 articles reporting outcomes in more than five robotically oper-
ated patients were identified. The number of centres performing
robot-assisted pancreatic surgery is also limited. Of 19 potentially
relevant articles, 14 were published by only three centres.
Another drawback may refer to the differences among the
studies in how outcomes were reported. Most of the studies did
not define outcomes; when outcomes were defined, definitions
differed across the studies. This makes it difficult to compare the
individual studies and to make comparisons between robot-
assisted surgery and other techniques.
The studies included in this review used different techniques:
not all resections were performed completely robotically. For
example, in some studies a hybrid approach that incorporated
both robot-assisted and conventional laparoscopic techniques was
used, or hand assistance was applied. This was not clearly reported
in most of the studies.
Most importantly, there is a probable selection bias in studies
reporting on robot-assisted surgery. Some of the studies explicitly
reported that patients were selected for robot-assisted approaches.
For example, one study cited an established diagnosis of adeno-
carcinoma as a reason for exclusion.24 Other studies operated only
in patients with benign or borderline malignant lesions.20,21
The initial concerns about the oncological outcomes of robot-
assisted surgery are not supported by the literature. In a large
series of patients undergoing open pancreatoduodenectomy, 9%
of resections resulted in positive margins.34 Systematic reviews of
conventional laparoscopic resections have reported findings of
histopathologically positive margins in 0.4% (varying from 0% to
11% in the individual studies in the review) of patients undergo-
ing pancreatoduodenectomy9 and 6% of patients undergoing
distal pancreatectomy.7 In the current systematic review, positive
margins were reported in 7.1% of all resections, 8.7% of pancrea-
toduodenectomies and 0% of distal pancreatectomies (although
these data were provided for only 19 of 85 patients undergoing
distal pancreatectomy).
Given the oncological outcomes, it should be noted that com-
parisons of pathological margins are problematic because reported
outcomes are strongly dependent on the definitions used in the
different studies.35 Moreover, there is a potential selection bias and
studies reported conversions that occurred for oncological reasons.
In addition, the short follow-up time makes it difficult to assess the
oncological safety of robot-assisted pancreatic surgery.
In conclusion, robot-assisted pancreatic surgery seems to be
safe and feasible in selected patients. In distal pancreatectomy, it
may increase the rate of spleen preservation compared with open
and laparoscopic approaches. However, studies with larger
numbers of patients, longer follow-up periods and validated defi-
nitions, such as the ISGPS definitions for complications, are
needed. To assess the potential benefits of robot-assisted surgery,
future studies should compare the results of robot-assisted pan-
creatic surgery with those of laparoscopic and open resections and
should include oncological outcomes among their data.
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